n.a. (VRX)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 17.20 / 28.45
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: Barclays' $29 Price Target on Valeant Is 'Very Right'

Jim Cramer: Barclays' $29 Price Target on Valeant Is 'Very Right'

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer thinks Barclay's $29 price target on Valeant Pharmaceuticals is "very right."

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three major averages closed Thursday's session in positive territory.

Jim Cramer on Bausch Health: This Stock Is a Buy

Jim Cramer on Bausch Health: This Stock Is a Buy

Valeant Pharmaceuticals is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Video: Jim Cramer on Oil, Occidental Petroleum, Bausch Health and Etsy

Video: Jim Cramer on Oil, Occidental Petroleum, Bausch Health and Etsy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

Video: Jim Cramer on the Iran Deal Decision, Hain Celestial & Caterpillar

Video: Jim Cramer on the Iran Deal Decision, Hain Celestial & Caterpillar

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.

Tesla Is Stalling Out

* My 2018 Tesla surprise is likely to be realized * Elon Musk has likely fractured some of the enthusiasm of his future bond and equity investors Surprise #15: Tesla Stalls Out Tesla  isn't able to successfully manufacture the Model 3 at scale. The ...

Call Activity Won't Tell You Anything (Part Six)

* Unusual call activity is actually often quite usual "Praise by name, criticize by category." -- Warren Buffett A month ago I added Lowe's  to the many stocks that recently experienced unusual call activity -- and turned out to be non-predictive of...

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Thursday.

Ackman and Pershing Square

"Also-Ran #2: Pershing Square Shutters: Despite a large permanent base of capital and Bill Ackman's strong record of resilience (and stubbornness!), Pershing Square closes and Ackman heads off to teach at Harvard Business School after his acrimoniou...

Call Activity Won't Tell You Anything (Part Five)

"Praise by name, criticize by category ." - Warren Buffett Earlier this month I added Lowe's to the many stocks that recently experienced unusual call activity -- and turned out to be non-predictive of further stock strength. Other recent false tell...

The Getting Too Giddy Factor

One of my favorite "thin reed indicators" is what I describe as the Getting Too Giddy factor. This occurs when talking heads in the media get too giddy about certain individual stocks and sectors. The getting giddy factor is a close cousin to Group ...

Valeant Pharmaceuticals Is Back to Playing Defense

Valeant Pharmaceuticals Is Back to Playing Defense

What do the charts and indicators look like today? Let's check.

Call Activity Won't Tell You Anything (Part Four)

"Praise by name, criticize by category." -- Warren Buffett Yesterday we add Lowe's to the many stocks that recently experienced unusual call activity  -- and turned out to be non-predictive of further stock strength. Other recent false tells include...

Multiple Creep... and More

Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...

My 15 Surprises for 2018 (Part Three)

Here we are in the home stretch of my 15 Surprises for 2018. Here are Surprises Nos. 11 through 15 (click here or see below for the previous surprises.)  Surprise #11: Company Share Buybacks Drop Dramatically Contrary to the consensus, slowing domes...

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.

Cramer: These CEOs Are Creating Value

Cramer: These CEOs Are Creating Value

Not all stocks are created equal and it's the CEOs who make the difference.

Jim Cramer: Why the Stock Market Isn't Falling

Jim Cramer: Why the Stock Market Isn't Falling

There are plenty of reasons why the stock market isn't falling, from defense and aerospace, to booming energy, to reduced regulation.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Is Valeant Pharmaceuticals Coming Back From the Dead?

Is Valeant Pharmaceuticals Coming Back From the Dead?

The stock is performing better than it has in a long time.

Ideas for the Week Ahead

Usually on Sundays I outline some ideas I want to deliver over the week, especially for Monday morning's opening missive. Here are some of my ideas that I have been contemplating for this week: * The Incredible Bull Market -- impervious to almost an...

Carpet Sweepers

A frequent theme of mine is the lack of follow-up and accountability by commentators and "talking heads" in the media of the many ideas that have soured.  Losers are part of the game -- and those who don't confess to mistakes are either lying or, as...

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

Valeant's Decline May Be Over

Valeant's Decline May Be Over

An inverse head-and-shoulders pattern has formed, suggesting a bullish reversal.

$20 Should Be Your Cutoff Point

$20 Should Be Your Cutoff Point

A stock that has been above $20 for years and then slips below $20 has a hard time finding new buyers.

Short the Stocks That Fall Below $20

Short the Stocks That Fall Below $20

A stock that has been above $20 for years, and then slips below $20, has a hard time finding new buyers.